18

                        UNITED STATES
            SECURITIES  AND  EXCHANGE  COMMISSION
                  Washington,  D.C.  20549
                              
                         FORM 10-QSB
                              
[x]     Quarterly report pursuant to Section 13 or 15(d) of
        the Securities Exchange Act of 1934   For the quarterly
        Period Ended September 30, 1997
                             or
[  ]    Transition Report Pursuant to Section 13 or 15(d) of
        the Securities Exchange Act of 1934   For the transition
        period from _____________to __________

Commission file number 0-19685
                              
                  METROVISION OF NORTH AMERICA, INC.
                     (Exact name of registrant as
                       specified in its charter)

                  New York               16-1276525
              (State or other            (IRS Employer
              jurisdiction of        Identification No.)
              incorporation or                             
               organization)

            75 South Church Street                        
          Pittsfield, Massachusetts           01201
            (Address of principal          (Zip Code)
              executive offices)

                          (413) 448-2111
                 (Registrant's telephone number,
                       including area code)

                           Not Applicable
           (Former name, former address and former fiscal
                year, if changed since last report)



Indicate  by check mark whether the registrant (1) has  filed
all  reports required to be filed by Section 13 or  15(d)  of
the  Securities Exchange Act of 1934 during the preceding  12
months  (or  for such shorter period that the registrant  was
required  to file such reports), and (2) has been subject  to
such filing requirements for the past 90 days.
Yes  X     No 
 
                              
                              
                              
            Applicable Only to Corporate Issuers

Indicate the number of shares outstanding of each of the
issuer's classes of common equity, as of the latest practical
date.

Common Stock, $.001 Par Value - 5,574,275 shares as of
November 13, 1997.

Transitional Small Business Issuer Format    (Check one)
Yes        No  X
 
             METROVISION OF NORTH AMERICA, INC.
                              
                            INDEX
                              
                              
                                                        Page #
Part I.  Financial Information                             
                                                           
Item 1.  Condensed Consolidated Financial Statements       
(Unaudited)
                                                           
Condensed consolidated balance sheets:                     
     December 31, 1996                                     
     September 30, 1997                                    3
                                                           
Condensed consolidated statements of operations:           
     Three months ended September 30, 1996 and 1997        
     Nine months ended September 30, 1996 and 1997         5
                                                           
Notes to condensed consolidated statements of cash         
flows:
     Nine months ended September 30, 1996 and 1997         6
                                                           
Item 2. Management's Discussion and Analysis of Financial        
Condition and Results of Operations                       10
                                                                 
Part II.  Other Information                                      
                                                                 
Item 6.                                                   16
                                                                 
Signatures                                                17
                              
               PART I - FINANCIAL INFORMATION
             METROVISION OF NORTH AMERICA, INC.
            CONDENSED CONSOLIDATED BALANCE SHEETS



                                   December    September
                                      31,         30,
                                     1996        1997
                                                   
                                              (Unaudited)
ASSETS                                                   
                                                         
CURRENT ASSETS                                           
Cash and cash equivalents            $58,291       $4,538
Accounts receivable, net of               --       93,088
allowances
Marketable securities                466,071           --
Prepaid expenses                          --        7,468
TOTAL CURRENT ASSETS                 524,362      105,094
                                                         
OPERATING EQUIPMENT                                      
Installations and equipment               --    2,532,813
Equipment and fixtures                    --      195,276
                                          --    2,728,089
Less:  accumulated depreciation           --             
                                              (2,395,371)
                                          --      332,718
OTHER ASSETS                                             
 Investment in York Hannover         701,179    1,258,885
Partnership
 Due from York Hannover                                --
Partnership                          160,747
 Due from related parties            245,267           --
 Goodwill, net of amortization            --      485,833
 Deposits                                 --        4,034
     TOTAL OTHER ASSETS            1,107,193    1,748,752
                                                         
TOTAL ASSETS                      $1,631,555   $2,186,564





                         (Continued)


             METROVISION OF NORTH AMERICA, INC.
            CONDENSED CONSOLIDATED BALANCE SHEET
                         (CONTINUED)



LIABILITIES and STOCKHOLDERS' DEFICIT

                                    December     September
                                       31,          30,
                                      1996          1997
                                                (Unaudited)
CURRENT LIABILITIES                                        
Accounts payable-trade                    $ --     $341,911        
Accrued salaries and commissions            --      203,015                     
Due to affiliates                      404,837      477,431
Accrued expenses                       370,835      277,488
Current portion of long term-debt    2,070,833    1,950,371
Current portion of notes payable       275,537           --
                                                           
TOTAL CURRENT LIABILITIES            3,122,042    3,250,216
                                                                              
Deferred income                        743,381      101,107
                                                           
PREFERRED STOCK, 5% SERIES A                --          649   
                                                                                
COMMON STOCKHOLDERS' DEFICIT                               
    Common stock, Class A                  100        5,574
    Unrealized loss on securities,                 
      net of taxes                    (32,040)           --
    Capital in excess of par value          --    1,077,190
    Retained deficit               (2,201,928)   (2,248,172)
                                                                                
TOTAL COMMON STOCKHOLDERS' DEFICIT (2,233,868)   (1,165,408)
                                   
                                                           
TOTAL LIABILITIES AND                                      
  STOCKHOLDERS DEFICIT              $1,631,555   $2,186,564
                              

    The accompanying notes are an integral part of these
             consolidated financial statements.


             METROVISION OF NORTH AMERICA, INC.
       CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
                         (Unaudited)


                                   Three months      Nine months
                                       ended            ended
                                   September 30,    September 30,
                                   1996      1997    1996     1997

NET REVENUES, including                                             
  equity in earnings of York                                        
  Hannover Partnership           $135,72 $363,964  $398,52  $934,348          
                                                                    
OPERATING COSTS AND EXPENSES                                        
Cost of sales                        - -   67,687      - -   109,176
Realized loss on sale of             - -       --      - -    66,914
securities
Selling, general, and            
  administrative                  19,852  278,165  251,743   528,146

Total Operating Costs             19,852  345,852  251,743   704,236
                                                       
OPERATING INCOME BEFORE                                
  DEPRECIATION AND AMORTIZATION  115,871   18,112  146,778   230,112
                                                                   
Depreciation and amortization        - -   37,500      - -    72,457
                                                                   
INCOME (LOSS) FROM OPERATIONS    115,871  (19,388) 146,778   157,655
                                               
                                                                   
Interest income                      - -      - -      - -      - -
Interest expense                 (74,620) (69,725)(214,442) (203,899)

NET INCOME (LOSS)                 41,251  (89,113) (67,664)  (46,244)
                                                                   
Less:  Preferred stock                                             
  dividend requirements              - -   45,041       --    90,082
                                                                   
NET INCOME (LOSS) APPLICABLE TO                                    
   COMMON STOCK                   41,251 (134,154) (67,664) (136,326)
                                                                   
NET INCOME (LOSS) PER COMMON    
  SHARE                           $41.25  ($0.02)  ($67.66)   $(0.02)
                                                                               
WEIGHTED AVERAGE NUMBER OF        
  SHARES                          1,000  5,574,275   1,000  5,574,275     


    The accompanying notes are an integral part of these
             consolidated financial statements.
             METROVISION OF NORTH AMERICA, INC.
       CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
                         (Unaudited)

                                                      Nine months ended
                                                        September 30
                                                       1996           1997
OPERATING ACTIVITIES                                                     
   Net Loss                                          $(67,664)  $(46,244)       
                                                               
Adjustment to reconcile net loss to net cash used in                          
operating activities:
       Provision for depreciation and amortization         - -     72,457      
       Amortization of deferred revenue                 (99,858)  (72,432)
       Realized loss on sale of marketable securities      - -     66,914
       Equity in earnings of York Hannover               
         Partnership                                   (232,755) (637,708)
   Changes in operating assets and liabilities:                          
           Decrease in accounts receivable (net)       108,274    132,304
           Decrease in inventory and other assets        8,059      3,230
           Increase (Decrease) in accounts payable                       
              and other accrued expenses               441,929   (146,681)     
                                                  
           NET CASH PROVIDED BY OPERATING                         
             ACTIVITIES                                157,985   (628,160)
                                                                         
INVESTING ACTIVITIES                                                     
       Capital expenditures for operating equipment        - -    (22,718)
       Proceeds from repayment of loans from affiliates    - -     10,002
       Payments received from York Hannover Partnership    - -     49,221      
       Loans to related parties, net of payments received (894)   (22,728)
       Distributions received from York Hannover        
         Partnership                                       - -     80,000
       Proceeds from Priority Distributions            130,000        - -
       Purchases of marketable securities               (1,000)       - -   
       Proceeds from sale of marketable securities         - -    399,198       
       Loans from related parties                          - -    477,431
       NET CASH PROVIDED BY INVESTING ACTIVITIES       128,374    970,406
                                                                         
FINANCING ACTIVITIES                                                     
       Principal payments on Short-Term Debt        
         Borrowings                                   (247,146)  (120,462)
       Principal payments on notes payable                 - -   (275,537)   
                                                            
       NET CASH USED IN FINANCING ACTIVITIES          (247,146)  (395,999)
                                                                         
NET INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS    39,213    (53,753)
Cash and cash equivalents at beginning of period        15,916     58,291
                                                                         
CASH AND CASH EQUIVALENTS AT END OF PERIOD             $55,129     $4,538
                              
                              
    The accompanying notes are an integral part of these
             consolidated financial statements.

METROVISION OF NORTH AMERICA, INC.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(UNAUDITED)

September 30, 1997


NOTE A-- MERGER AND BASIS OF PRESENTATION


On  April  1,  1997,  MetroVision  of  North  America,  Inc.
("MetroVision" or "the Company") consummated a  merger  (the
"Merger")    as   a   result   of   which   York    Hannover
Pharmaceuticals,   Inc.   ("York   Hannover")   a    Florida
corporation,  merged  with and into the  Company,  with  the
Company  as  the  surviving  corporation,  pursuant  to   an
Agreement and Plan of Merger dated as of May 10, 1996  among
the  Company  and  York  Hannover (the "Merger  Agreement").
Under  the  terms  of  the Merger Agreement,  York  Hannover
distributed all of its assets and liabilities to Stockbridge
Investment  Partners, Inc. prior to the  Merger  except  for
York  Hannover's  40% interest in York Hannover  Partnership
and  York  Hannover's  outstanding  debt  under  a  National
HealthCare   L.P.   promissory  note  and  related   accrued
interest.   Pursuant  to the Merger Agreement,  among  other
things:  (i) the Company changed its corporate name to  York
Hannover  Health  Care  Inc.  (subject  to  receipt  of  all
necessary regulatory consents which are still pending);  and
(ii)  each  share  of  York Hannover  Pharmaceuticals,  Inc.
Common Stock outstanding on April 1, 1997 was converted into
4,000  shares of the Company's Common Stock, or an aggregate
of   4,000,000   shares   of  Common   Stock,   constituting
approximately   71.8%  of  the  shares   of   Common   Stock
outstanding giving effect to the Merger.  As a result of the
Merger, the Company has shifted its primary business to that
conducted  by  York Hannover, the provision of  prescription
and   non  prescription  medications  and  pharmacy  related
services to nursing homes and similar facilities.

In  addition  to  the  shares  of  Common  Stock  issued  to
Stockbridge  in  the  Merger, each  of  Messrs.  Clarke  and
Cummings were issued warrants to purchase 750,000 shares  of
the  Company's Common Stock, exercisable in three cumulative
equal  annual installments, at exercise prices ranging  from
$.63  to  $.945  per  share.  If all of such  warrants  were
exercised  (and assuming no other increases in the Company's
capital   stock),   Messrs.  Clarke   and   Cummings   would
beneficially   own,   directly  and   through   Stockbridge,
approximately 78.7% of the outstanding Common Stock.

On  April 1, 1997, pursuant to shareholder approval  at  the
Special  Meeting  of  Shareholders on  April  1,  1997,  the
Company  filed  an amendment to its Restated Certificate  of
Incorporation to effect a 1 for 4.6 reverse stock  split  of
the Common Stock effective April 1, 1997.  The shares issued
in the Merger give effect to the reverse stock split.

The  Merger  has been accounted for as a reverse acquisition
of  MetroVision by York Hannover in a transaction  accounted
for using the purchase method of accounting as prescribed by
Accounting Principals Board Opinion No. 16.  In the  reverse
acquisition transaction, York Hannover has been  treated  as
the acquirer for financial reporting purposes.  Accordingly,
the  historical financial statement of the Company have been
changed  to  reflect the historical financial statements  of
York Hannover Pharmaceuticals, Inc.  The purchase method  of
accounting  prescribes that the acquiring  company  allocate
the  cost of an acquired company, including the expenses  of
the  acquisition,  to  the assets acquired  and  liabilities
assumed  as of the date of the acquisition based upon  their
fair  values.   The  Company has determined  that  the  fair
market value of MetroVision's assets less liabilities as  of
March  31,  1997 was $300,000 compared to a  book  value  of
negative   $198,  290.   Therefore,  the  Company   recorded
goodwill  of $498,290 as of April 1, 1997.  The goodwill  is
being amortized over twenty years.






The  accompanying unaudited condensed consolidated financial
statements  have been prepared in accordance with  generally
accepted   accounting  principles  for   interim   financial
information  and  with the instructions to Form  10-QSB  and
Article  10  of Regulation S-X.  Accordingly,  they  do  not
include  all  of the information and footnotes  required  by
generally   accepted  accounting  principles  for   complete
financial  statements.  In the opinion  of  management,  all
adjustments   (consisting  of  normal  recurring   accruals)
considered  necessary  for  a fair  presentation  have  been
included.   Operating  results for  the  nine  months  ended
September  30,  1997 are not necessarily indicative  of  the
results  that  may be expected for the year ending  December
31, 1997.


NOTE B--NEW PRONOUNCEMENTS

Statement  of  Financial  Accounting  Standards   No.   128,
"Earnings per Share" ("SFAS 128"), has been issued effective
for fiscal periods ending after December 15, 1997.  SFAS No.
128  establishes  standards  for  computing  and  presenting
earnings  per share.  The Company is required to  adopt  the
provisions  of SFAS No. 128 in the fourth quarter  of  1997.
Under  the standards established by SFAS 128, basic earnings
per share is computed by dividing net income by the weighted
average number of common shares outstanding during the year.
Due  to the Company's option and warrant prices compared  to
the  respective  market  value  of  those  instruments,  the
effects  of  SFAS  No. 128 have no impact to  the  Company's
reported earnings per share amounts.


NOTE C - INVESTMENT IN YORK HANNOVER PARTNERSHIP

During  1995, York Hannover Pharmaceuticals, Inc.  formed  a
partnership   ("York   Hannover   Partnership"   or     "the
Partnership") with United Professional Companies,  Inc.  for
the   purpose   of  operating  a  business  which   provides
institutional   pharmacy,  infusion   therapy,   third-party
billing, medical equipment and supplies, respiratory therapy
and   other  services.   Pursuant  to  the  terms   of   the
partnership  agreement,  York Hannover  contributed  to  the
Partnership  all  of its furniture and equipment,  inventory
and  existing contracts with nursing facilities  to  provide
services and products.  York Hannover's 40% interest in  the
Partnership   is  recorded  using  the  equity   method   of
accounting.


 METROVISION OF NORTH AMERICA, INC.


Item  2.   MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL
CONDITION AND RESULTS OF OPERATIONS

Results of Operations

   Three Months Ended September 30, 1997 Compared to Three
                  Months September 30, 1996

The   1996  historical  period  includes  three  months   of
operations  of York Hannover Pharmaceuticals,  Inc.  and  no
operations  of  MetroVision due to the  purchase  accounting
treatment  effective April 1, 1997  (see note A to Financial
Statements).   The  1997  historical period  includes  three
months of operations of York Hannover Pharmaceuticals,  Inc.
and three months of operations of MetroVision subsequent  to
the  Merger  effective  April 1, 1997.   As  a  result,  for
purposes  of  Management's  Discussion  and  Analysis,   the
following  unaudited pro forma income statement  information
for  the  three  months ended September 30,  1996  has  been
presented   along  with  the  unaudited  historical   income
statement  information for the three months ended  September
30,  1997  in order to present both periods in a  comparable
format.   The  unaudited pro forma information is  presented
for  informational  purposes only  and  is  not  necessarily
indicative of the operating results that would have occurred
had  the Merger been consummated on January 1, 1996 nor  are
they  necessarily  indicative of future  operating  results.
The   following  summarized  unaudited  pro   forma   income
statement  information for the three months ended  September
30,  1996 for the Company is presented as though the  Merger
had been entered into on January 1, 1996:
                                  Pro Forma       Historical
                                     Three       Three Months
                                    Months
                                     Ended           Ended
                                  September        September
                                   30, 1996        30, 1997
                                                             
Net revenues                         $302,000        $364,000
Cost of sales                          63,000          68,000
Selling, general and administrative   188,000          278,000
Write-down of contract rights and                              
installation assets                   608,000             - -
Other expenses                        244,000         108,000
Net loss                             (801,000)        (90,000)
Less: preferred stock dividend                               
  requirements                        (45,000)        (45,000)        
                                             
Net loss applicable to common stock ($846,000)      ($135,000)

The  pro  forma adjustments include the elimination  of  the
effects  of  York Hannover's operations that  were  spun-off
prior to the Merger and the effect of all necessary purchase
accounting adjustments.

Net  Revenues.   The Company derives its revenues  from  the
sale or barter of advertising and information provider spots
on  the  Commuter Channel, the sale of complete  systems  to
Transit  Authorities  and equity in  the  earnings  of  York
Hannover  Partnership. Net revenues  for  the  three  months
ended  September 30, 1997 were $364,000 an increase of 20.5%
or  $62,000 from pro forma net revenues of  $302,000 for the
three  months ended September 30, 1996.   This  increase  in
net  revenues for the three months ended September 30,  1997
was  primarily associated with an increase in earnings  from
York Hannover Partnership.

Cost  of  Sales.   Cost  of  sales  consists  primarily   of
commissions paid to installed transit systems, the  cost  of
system   installations,  maintenance  costs,  and   software
licensing  fees.   Commissions to installed transit  systems
are  based  on a percentage of revenues.  Maintenance  costs
are directly related to increases in the number of installed
television  monitors and computers.  Cost of sales  for  the
three  months  ended  September 30, 1997  were  $68,000,  an
increase of  7.9% or $5,000 from pro forma cost of sales  of
$63,000 for the three months ended September 30, 1996.  This
increase  was primarily the result of an increase  in  costs
associated with system sales partially offset by a  decrease
in software licensing fees.

Selling,  General  and  Administrative  Expenses.   Selling,
general  and  administrative expenses for the  three  months
ended  September  30,  1997 were $278,000,  an  increase  of
47.9%  or   $90,000 from selling, general and administrative
expenses  of  $188,000 for the three months ended  September
30,  1996. This increase was primarily attributable to costs
incurred  in  connection with  contemplated acquisitions  by
the  Company  partially  offset by a decrease  in  salaries,
wages  and  related employee costs resulting from reductions
in sales, marketing and operations employees.

Write-down  of Contract Rights and Installation Assets.  For
the  three  months  ended September  30,  1996,  MetroVision
recorded  a charge of $607,761 to reduce the carrying  value
of  certain  purchased  contract  rights,  and  installation
equipment   for   the  New  York  area  airports   and   The
Massachusetts Bay Transit Authority ("MBTA")  to  their  net
realizable value.  Pursuant to the notification by the  Port
Authority  of  is  intent  to  terminate  the  contract  and
MetroVision's  decision  to halt construction  of  the  MBTA
installation  related  to litigation and  the  inability  to
generate  significant revenues, MetroVision has  recorded  a
charge  to  recognize the impairment in the  value  of  long
lived assets.

Other    Expenses.    Other   expenses   primarily   include
depreciation  and  interest expense on  a  note  payable  to
National  HealthCare  L.P.  Other  expenses  for  the  three
months ended September 30, 1997 were $108,000, a decrease of
55.7%  or $136,000 from other expenses of $244,000  for  the
three  months  ended September 30, 1996.  This  decrease  is
primarily the result of a reduction in depreciation  expense
associated  with the significant nonrecurring writedowns  of
the  Company's  operating equipment to their net  realizable
value during the three months ended September 30, 1996.


Nine Months Ended September 30, 1997 Compared to Nine Months
                  Ended September 30, 1996


The   1996   historical  period  includes  nine  months   of
operations  of York Hannover Pharmaceuticals,  Inc.  and  no
operations  of  MetroVision due to the  purchase  accounting
treatment  effective  April 1, 1997.   The  1997  historical
period  includes nine months of operations of York  Hannover
Pharmaceuticals,  Inc.  and  six  months  of  operations  of
MetroVision  subsequent to the Merger.   As  a  result,  for
purposes  of  Management's  Discussion  and  Analysis,   the
following  unaudited pro forma income statement  information
has  been presented to reflect nine months of operations  of
both  entities.   The  unaudited pro  forma  information  is
presented  for  informational  purposes  only  and  is   not
necessarily indicative of the operating results  that  would
have occurred had the Merger been consummated on January  1,
1996 nor are they necessarily indicative of future operating
results.   The  following  summarized  unaudited  pro  forma
income statement information for the Company is presented as
though the Merger had been entered into on January 1, 1996:



                                Pro Forma     Pro Forma
                               Nine Months   Nine Months
                                  Ended         Ended
                              September 30, September 30,
                                  1996           1997
                                                          
Net Revenues                      $917,000      $1,050,000
Cost of sales                      286,000         182,000
Selling, General and               
  administrative                   628,000         664,000
Other Expenses                     583,000         393,000
Write-down of contract rights                               
and installation assets            608,000             - -
Net Income (loss)               (1,188,000)       (189,000)
Less: preferred stock                                     
dividend requirements              135,000)       (135,000)
Net Loss applicable to common     
  stock                        ($1,323,000)      ($324,000)



The  pro  forma adjustments include the elimination  of  the
effects  of  York Hannover's operations that  were  spun-off
prior to the Merger and the effect of all necessary purchase
accounting adjustments.


Net  Revenues.  Net  Revenues  for  the  nine  months  ended
September 30, 1997 were $1,050,000, an increase of  14.5% or
$133,000  from net revenues of $917,000 for the nine  months
ended September 30, 1996.  This increase in net revenues for
the nine months ended September 30, 1997 was associated with
an  increase  in  earnings from York  Hannover  Partnership,
partially offset by a decrease in advertising, news provider
and system sales revenues.

Cost  of  Sales.   Cost of sales for the nine  months  ended
September  30, 1997 were $182,000, a decrease of   36.3%  or
$104,000 from cost of sales of $286,000 for the nine  months
ended  September 30, 1996.  This decrease was primarily  the
result  of  a decrease in software licensing fees and  costs
associated  with system sales as the Company  redirects  its
focus to the business of York Hannover Pharmaceuticals, Inc.
following the Merger.

Selling,  General  and  Administrative  Expenses.   Selling,
general  and  administrative expenses for  the  nine  months
ended September 30, 1997 were $664,000, an increase of  5.7%
or    $36,000   from  selling,  general  and  administrative
expenses of $628,000 for the nine months ended September 30,
1996.   This  increase was primarily attributable  to  costs
incurred  in connection with the merger of the Company  with
York  Hannover Pharmaceuticals, Inc. partially offset  by  a
decrease  in  salaries,  wages and  related  employee  costs
resulting from reductions in sales, marketing and operations
employees.

Write-down of Contract Rights and Installation Assets.   For
the  nine  months  ended  September  30,  1996,  MetroVision
recorded  a charge of $607,761 to reduce the carrying  value
of  certain contract rights, and installation equipment  for
the New York area airports and The Massachusetts Bay Transit
Authority ("MBTA") to their net realizable value.   Pursuant
to  the  notification by the Port Authority of is intent  to
terminate  the contract and MetroVision's decision  to  halt
construction of the MBTA installation related to  litigation
and   the   inability  to  generate  significant   revenues,
MetroVision   has  recorded  a  charge  to   recognize   the
impairment in the value of long lived assets.

Other    Expenses.    Other   expenses   primarily   include
depreciation  and  interest expense on  a  note  payable  to
National HealthCare L.P.  Other expenses for the nine months
ended September 30, 1997 were $393,000, a decrease 32.6%  or
$190,000 from other expenses of $583,000 for the nine months
ended  September 30, 1996.  This decrease was primarily  the
result of a decrease in depreciation expense as a result  of
the  significant  nonrecurring writedowns of  the  Company's
operating equipment to their net realizable value during the
nine months ended September 30, 1996.




Liquidity and Sources of Capital

The following discussion regarding liquidity and sources  of
capital is derived from the historical balance sheet of York
Hannover  and  does not include MetroVision's  December  31,
1996  balance sheet accounts due to the purchase  accounting
treatment effective April 1, 1997.

At  September  30,  1997,  the Company had negative  working
capital  of  $3,145,122 and a ratio  of  current  assets  to
current  liabilities  of  (.03)  as  compared  to  (.28)  at
December  31, 1996.  Cash was $58,291 at December  31,  1996
and  $4,538  at  September 30, 1997.  Marketable  securities
decreased $446,041 to $0 at September 30, 1997 from $446,041
at  December  31, 1996.  In January and February  1997,  the
Company  received proceeds aggregating to $399,198 from  the
sale   of  its  Marketable  Securities.   These  funds  were
primarily  used  to  repay margin loans of  $275,537,  notes
payable   to  former  shareholders  of  $94,199  and   other
operating expenses.  Retained deficit increased $46,244 from
$2,201,928  at December 31, 1996 to $2,248,172 at  September
30,  1997.  This increase is the result of the net loss  for
the period ending September 30, 1997.

On  March  10,  1997, the Company entered into an  agreement
with  an  unaffiliated third party pursuant  to  which  such
party  was  granted an option to purchase the operating  and
fixed   assets  of  MetroVision  constituting  the  Commuter
Channel  assets  for an aggregate of $400,000  in  cash  and
debentures.  This option automatically expired September  1,
1997.  The Company received $25,000 in consideration for the
option.

On  March  21, 1997, the Company borrowed $14,750  from  the
Company's  former President (who is also a director  of  the
Company). The loan was repaid with accrued interest at  10%.
In  consideration of the promissory note, the Company issued
40,710  common stock purchase warrants at $.125  per  share.
The  exercise price represents the fair market value of  the
Company's  common stock on the date of grant.  The  warrants
expire in March 2002.

As of September 30, 1997, the Company has received unsecured
loans  from  affiliates  totaling  $477,431.   These  loans,
including all accrued and unpaid interest at a rate  of  10%
per  annum,  are  due  no  later  than  May  1,  1998.    No
consideration was given for this loan.

The  Company  has entered into an agreement wherein  it  has
received  purchase  orders amounting to  approximately  $1.3
million  with  New  Jersey Transit to install  and  maintain
approximately  21 transit stations, of which $1,028,000  has
been received to date.

As  of  September 30, 1997, the Company's primary asset  was
its   ownership   of  a  40%  interest  in   York   Hannover
Partnership.  For the nine months ended September 30,  1997,
the  Company's  net  income  from  the  Partnership  totaled
$637,708.  As  a  result  of  the Partnerships obligation to
repay  loans  made by its  majority  partner pursuant to the
Partnership Agreement, the Company has received proceeds of 
$80,000 in 1997.  In as much as the Company will continue to
have  a high  level of  operating  expenses  (including  the 
salaries  and  benefits  of executive,  marketing, and other 
personnel),  the  Company   anticipates  that   losses  will  
continue until  the Company  generates  sufficient  revenues 
to offset its operating  costs.  The Company is not currently  
generating sufficient cash flow to fund its operations and is 
dependent  on  other  financing  in  order  to  sustain   its 
operations.  To date, such financing has been  received  from 
affiliates  of the  Company and the Company is dependent upon 
such  financing  to   meet  its  obligations.   The   Company 
believes   that the  generation  of   revenues  to  meet  its 
obligations without external financing  will be substantially
dependent upon  the success of any business opportunities  of 
which the Company identifies following the recently completed
merger   with  York  Hannover  as  well  as  from revenues in  
distribution from York Hannover  Partnership.  There  can  be  
no assurance, however, that the  Company  will   be successful  
in   its  new  business  endeavors  or   be able  to  generate 
significantly  increased revenues or  ever  achieve profitable 
operations.

In  the  event the Company's plans change or its assumptions
change or prove inaccurate or projected cash flows prove  to
be  insufficient to fund operations,  the Company  would  be
required to seek additional financing.  The Company  has  no
current   arrangements  with  respect  to  or   sources   of
additional financing except for the current working  capital
affiliated  financing, and  there can  be no  assurance that
any   financing  will  be  available  to  the   Company   on
commercially reasonable terms, if at all.  Any inability  to
obtain  additional  financing will likely  have  a  material
adverse  effect on the Company, including possibly requiring
the   Company   to  significantly  curtail  or   cease   its
operations.  The Company had outstanding as of September 30,
1997  a term loan of $1,950,371 due to NHCLP.  Although  the
stated  maturity  date  of  the indebtedness  due  NHCLP  is
January  1999,  the Company is currently not  in  compliance
with certain covenants under the loan agreement relating  to
indebtedness,  principally  relating  to  its   failure   to
maintain  positive working capital.  As  a  result  of  such
noncompliance,  the  $1,950,371 principal  amount,  together
with  accrued interest thereon, is due December  1997.   The
Company  does not possess the financial resources  necessary
to meet this payment obligation absent of obtaining external
financing, whether from an equity offering or otherwise.  In
the  event  the  Company  is unable  to  meet  this  payment
obligation, or if the loan is not renegotiated, NHCLP, as  a
secured  creditor, has the right to take  possession  of  or
otherwise  sell  the 40% partnership interest  in  the  York
Hannover Partnership in satisfaction of the indebtedness and
may  seek  recourse against the Company's other  assets,  if
necessary.

As  a  minority partner, the Company does not  have  control
over  distributions made by York Hannover Partnership.   All
Partnership   distributions  are   also   subject   to   the
availability of York Hannover Partnership cash.


                              
                              
                              
                 PART II - OTHER INFORMATION
                              
             METROVISION OF NORTH AMERICA, INC.




Item 6. EXHIBITS AND REPORTS ON FORM 8-K

(a)  Exhibits. None.


(b)   No  Reports  on Form 8-K were filed during  the  three
      months ended September 30, 1997.


             METROVISION OF NORTH AMERICA, INC.
                              
                         SIGNATURES




Pursuant to the requirements of the Securities Exchange  Act
of  1934, the registrant has duly caused this report  to  be
signed  on  its  behalf  by the undersigned  thereunto  duly
authorized.






                            METROVISION OF NORTH AMERICA, INC.
                                       (Registrant)
                                                              
Date:  Nov 13, 1997                 /s/Thomas M. Clarke
                                Thomas M. Clarke, President
                                 (Duly authorized Officer)
                                             
                                             
Date: Nov 13, 1997                 /s/ David M. Fancher
                                     David M. Fancher
                                  Chief Financial Officer
                             (Principal Financial & Accounting
                                         Officer)
METROVISION OF NORTH AMERICA, INC. June 30

SIGNATURES




     Pursuant to the requirements of the Securities Exchange
Act  of 1934, the registrant has duly caused this report  to
be  signed  on its behalf by the undersigned thereunto  duly
authorized.





                            METROVISION OF NORTH AMERICA, INC.
                                       (Registrant)
                                                              
Date:  Nov 13, 1997                          
                               Thomas M. Clarke, President
                                (Duly Authorized Officer)
                                             
                                             
Date: Nov 13, 1997                           
                                     David M. Fancher
                                 Chief Financial Officer
                            (Principal Financial & Accounting
                                         Officer)